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a b s t r a c t
A rheumatoid arthritis patient was treated for two years with methotrexate and lefluno-
mide combination therapy. The evolution was uneventful until she had clopidogrel, simv-
astatin, isosorbide, aspirin and omeprazole added to medication due to acute myocardial 
infarction. Four weeks after this, she was hospitalized with severe leukopenia. 
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Leucopenia grave em paciente com artrite reumatoide tratada com 
combinação de metotrexato e leflunomida
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r e s u m o
Apresentamos o caso de uma paciente com artrite reumatoide tratada por dois anos com 
associação de metotrexato e leflunomida. A paciente foi internada com leucopenia grave 
quatro semanas após acrescentar ao esquema medicamentoso as drogas clopidogrel, iso-
sorbida, sinvastatina, AAS e omeprazol.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Methotrexate (MTX) is considered as a basic drug for most ther-
apeutic regimes for rheumatoid arthritis worldwide.1 However, 
its use as monotherapy, or associated only with low dose cor-
ticosteroids, is often insufficient for remission induction or to 
achieve acceptable levels of disease activity. Therefore, various 
combination therapies have been tested in order to increase 
the efficiency of MTX. Among these, the association with leflu-
nomide (LEF) proved the most effective, with synergistic effects 
demonstrated in several studies.2 Nevertheless, the possibility 
of cumulative toxicity of the two drugs is always a concern, 
whenever this drug combination is prescribed.
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Case report
In January 2011, a 68-year-old woman was hospitalized in 
the Department of Internal Clinic of HSPE with dyspnea on 
exertion, fatigue, lack of appetite, diarrhea, cough, fever and 
chills. The patient showed a regular general state and her 
admission was justified by the results of a CBC in the emer-
gency department: Hemoglobin (HB): 10 mg/dL (HTC: 31.2, 
MCV: 92.3, MCHC: 32.0, RDW: 16.5); leukocytes: 980/mm3 
(neutrophils, 500; lymphocytes, 300; eosinophils, 80; and 
monocytes, 100); platelets: 182.000/mm3.
Her pathological history revealed rheumatoid arthritis 
for six years, mainly with proximal interphalangeal joints, 
metacarpophalangeal joints and wrists involved. In January 
2008 she started treatment with methotrexate 15 mg weekly 
with folic acid supplementation at a dose of 5 mg two days 
after taking MTX. In January 2010 the patient had persistent 
synovitis in the mentioned joints, requiring 10 mg/day of 
prednisone to control the painful symptoms. On this occa-
sion, the addition of leflunomide 20 mg/day started, with re-
duction of methotrexate to 10 mg weekly and maintenance 
of the replacement schedule of folic acid.
With this therapeutic regime, the patient obtained good 
clinical response, remission of synovitis and progressive im-
provement of joint pain. She did not relate significant side 
effects during the year of 2010. 
In October 2010, her medical record indicated outpatient 
care; the patient was virtually symptom free and without sy-
novitis. In this occasion, a CBC yielded the following results: 
HB 10.8 mg/dL; leukocytes: 4850/mm3 (neutrophils, 3500; 
eosinophils, 200; lymphocytes, 700; and monocytes, 450); 
platelets: 290.000/mm3. Liver enzymes values were   within 
the normal range.
In December 2010, the patient was admitted to the Cor-
onary Care Unit of HSPE with typical precordial pain, and 
a diagnosis of acute myocardial infarction (AMI) was con-
firmed. Due to this event, she began clopidogrel, aspirin, iso-
sorbide, simvastatin and omeprazole continuously, in addi-
tion to medication for rheumatoid arthritis, and maintained 
this therapeutic regime until new hospitalization, reported 
above, four weeks after AMI.
Progression
In the ward, the patient received antibiotic coverage accord-
ing to the protocol for patients with febrile leukopenia. Con-
sidering the possibility of myelotoxicity, MTX and LEF were 
suspended, the dose of prednisone was increased to 20 mg/
day, and folinic acid was initiated at a dose of 15 mg/day. 
On this therapeutic scheme the patient showed rapid im-
provement. A CBC obtained three days after the beginning 
of the replacement with folinic acid showed the following 
results: HB: 8.7 mg/dL (HTC 28, MCV 81); leukocytes: 3.130 
(neutrophils, 220; eosinophils, 200; lymphocytes, 430; mono-
cytes, 300); platelets: 202,000; VHS: 80. 
Given a favorable and constant evolution, the patient was 
discharged after 10 days without antibiotics and only with 
her heart medication plus folinic acid 15 mg/d and predni-
sone 5 mg/d. 
In the last follow-up (May, 2011), the patient was asymp-
tomatic, with the following laboratory data: ALT: 12 U/L, AST 
13 U/L; hemoglobin: 12.6 mg/dL; MCV 88.3 fL; WBC: 8700/
mm3 (neutrophils, 6700; eosinophils, 300; lymphocytes, 1200; 
monocytes, 500); platelets: 398,000.
Discussion
Although not all mechanisms by which MTX exerts its anti-
inflammatory activity in rheumatoid arthritis are known, 
its primary pharmacological action is to block the enzyme 
folate reductase by interfering with the synthesis of nucleo-
tides in the purine pathway. 
Leflunomide (LEF) inhibits the synthesis of nucleotides 
in the pirimidine pathway, with a possible synergistic action 
with MTX in reducing the activity of immunocompetent cells. 
The concomitant use of MTX and LEF provides additional 
benefits, compared to each of these agents as monotherapy.2
However, the combination of MTX with LEF is considered 
risky, for there is the possibility of an additive toxicity of 
both drugs on liver, lung and bone marrow. For that reason, 
their association is formally contraindicated in USA. In Bra-
zil, Australia and New Zealand, many rheumatologic centers 
accept this association, which is considered safe in relation 
to the possibility of liver toxicity.3 Thus, this combination 
was seen as another step in RA therapeutic pyramid.4
In the present case, a LEF-MTX combination showed a 
good result in the control of rheumatoid disease, providing 
a smooth evolution until a new clinical event (AMI) required 
the addition of drugs of common usage for the clinical situ-
ation related, but this new circumstance probably interact-
ed in the genesis of myelotoxicity, resulting in leukopenia. 
Among the drugs with positive interaction with MTX, we 
found ASA5 and omeprazole in the patient’s prescription. 
These drugs can increase the persistence and availability of 
MTX in plasma.6,7
Conflicts of interest
The authors declare no conflicts of interest.
R E F E R E N C E S
1. Cronstein B. Methotrexate - the anchor drug - an 
introduction. Clin Exp Rheumatol. 2010; (Suppl. 61):S1-S2.
2. Singer O, Gibofsky A. Methotrexate versus leflunomide 
in rheumatoid arthritis: what is new in 2011? Curr Opin 
Rheumatol 2011;23:288-292.
3. Alves JANR, Fialho SCMS, Morato EF, Castro GRW, 
Zimmermann AF, Ribeiro GG, et al. Toxicidade hepática é 
rara em pacientes com artrite reumatoide usando terapia 
combinada de leflunomida e metotrexato. Rev Bras Reumatol. 
2011;51:138-144. 
4. Savage RL. Leflunomide in combination therapy for 
rheumatoid arthritis. Drug Saf. 2010;33: 523-526.
5. Jacomini LCL, Silva NA. Risks of drug nutrient interaction for 
the elderly in long-term care institutions. Rev Bras Reumatol. 
2011;51: 161-174.
154 R E V  B R A S  R E U M A T O L .  2 0 1 4 ; 5 4 ( 2 ) : 1 5 2 – 1 5 4
6. Santucci R, Leveque D, Kemmel V, Lutz P, Gérout AC, NGuyen 
A, et al. Severe intoxication with methotrexate possibly 
associated with concomitant use of proton pump inhibitors. 
Anticancer Res. 2010;30:963-966.
7. Bagatini F, Blatt CR, Maliska G, Trepash GV, Pereira 
IA, Zimmermann AF, et al. Potenciais interações 
medicamentosas em pacientes com artrite reumatoide. Rev 
Bras Reumatol. 2011;51:20-39. 
